SEC Form 4 · accession 0001209191-18-063993
Tracon Pharmaceuticals, Inc. · TCON
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Charles Theuer
Officer — President and CEO · Director
Period of report
Dec 21, 2018
Accepted (ET)
Dec 21, 2018 · 6:32 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001394319
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Dec 21, 2018 | P | 49,000 | $0.6576 | A | 132,855 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.6286 to $0.6769, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above
- F2Includes 3,500 shares acquired on April 20, 2018 and 3,500 shares acquired on October 19, 2018, pursuant to the Issuer's 2015 Equity Incentive Plan.